Predicting smell recovery in patients with nasal polyps treated with dupilumab
Olfactory Cleft Obstruction and Electrophysiological Olfactory Bulb Generated Beta Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
This study is trying to see if certain factors can help predict how well people with nasal polyps will recover their sense of smell after being treated with dupilumab.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Northwestern University Academic / other |
| Drugs / interventions | dupilumab |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT06892704 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify predictors for the restoration of the sense of smell in patients suffering from chronic rhinosinusitis with nasal polyps who are being treated with dupilumab. It will assess the degree of olfactory cleft obstruction and measure electrophysiological signals related to breathing and sniffing behavior. Participants will be monitored over a six-month period to evaluate changes in their olfactory function. The study seeks to understand the relationship between these factors and the potential recovery of smell.
Who should consider this trial
Good fit: Ideal candidates include individuals with a well-documented history of chronic rhinosinusitis with nasal polyps and a stable olfactory deficit lasting more than three months.
Not a fit: Patients who do not have chronic rhinosinusitis with nasal polyps or have not experienced a stable olfactory deficit may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify which patients are most likely to regain their sense of smell after treatment with dupilumab.
How similar studies have performed: While this approach is observational, similar studies have shown promise in understanding olfactory recovery in related conditions, though this specific predictive methodology may be novel.
Eligibility criteria
Show full inclusion / exclusion criteria
* Well documented history of CRSwNP * BSIT age/sex classified as "abnormal" score * Self-reported stable olfactory deficit of moderate to severe quality \> 3 months * Prior endoscopic sinus surgery \>3 months, \<10 years prior
Where this trial is running
Chicago, Illinois
- Northwestern University Feinberg School of Medicine — Chicago, Illinois, United States (Recruiting)
Study contacts
- Study coordinator: Clinical Coordinator
- Email: aditi.agarwal@northwestern.edu
- Phone: 312 6958182
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.